Teva Pharmaceutical Q4 Adjusted EPS $1.00 Beats $0.76 Estimate, Sales $4.46B Beat $3.99B Estimate
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. (TEVA) reported Q4 adjusted earnings per share (EPS) of $1.00, surpassing the consensus estimate of $0.76 by 31.58%. This represents a 40.85% increase from the $0.71 EPS reported in the same quarter last year. Quarterly sales reached $4.46 billion, exceeding the consensus estimate of $3.99 billion by 11.58% and marking a 14.75% increase from the $3.88 billion in sales reported in the same period last year.
January 31, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical Industries Ltd. reported strong Q4 earnings, with both EPS and sales figures exceeding analyst estimates, indicating significant year-over-year growth.
Teva's earnings beat is likely to be viewed positively by investors, as it suggests the company is performing better than expected. This could lead to increased investor confidence and a potential short-term rise in the stock price. The substantial beat in both EPS and sales, along with the year-over-year growth, reinforces the positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100